~~<i id='FA55BD671E'><strike id='FA55BD671E'><tt id='FA55BD671E'><pre id='FA55BD671E'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：entertainment 2025-10-02 21:08:52 Page View：6422

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Obamacare plans could cover weight loss drugs
Next article： ChatGPT in medicine: STAT answers readers' burning questions

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Congress may force more Covid

HouseOversightChairmanBradWenstrup(R-Ohio)AnnaMoneymaker/GettyImagesTheHealthandHumanServicesDepartm

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

FDA warns medical device makers about rise in fabricated data

ManuelBalceCeneta/APAnincreasingnumberofmedicaldevicecompaniesaresubmittingfabricatedandunreliableda

WSS

explore

explore

Wikipedia

explore

FDA warns medical device makers about rise in fabricated data